The future of tuberculosis vaccinology

Reichman and Hershfield's Tuberculosis: A Comprehensive, International Approach, Third Edition

Volumn , Issue , 2006, Pages 1153-1168

  Griffin, Ruth ^a   Young, Douglas ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85016695872     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (78)

1. Smith PG, Ross AR. Epidemiology of tuberculosis. In: Bloom BR, ed. Tuberculosis: Pathogenesis, Protection, and Control. Washington, D.C.: American Society of Microbiology, 1994.
2. van Rie A, Warren R, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999; 341(16):1174-1179.
3. al-Kassimi FA, al-Hajjaj MS, al-Orainey IO, et al. Does the protective effect of neonatal BCG correlate with vaccine-induced tuberculin reaction? Am J Respir Crit Care Med 1995; 152(5 Pt 1):1575-1578.
4. Colditz GA, Berkey CS, Mosteller F, et al. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: metaanalyses of the published literature. Pediatrics 1995; 96(1 Pt 1):29-35.
5. Miceli I, de Kantor IN, Colaiacova D, et al. Evaluation of the effectiveness of BCG vaccination using the case-control method in Buenos Aires, Argentina. Int J Epidemiol 1988; 17(3):629-634.
6. Bloom BR, Fine PEM. The BCG experience: implications for future vaccines against tuberculosis. Washington, D.C.: American Society for Microbiology, 1994.
7. Fine PE. The BCG story: lessons from the past and implications for the future. Rev Infect Dis 1989; 11(suppl 2):S353-S359.
8. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995; 346(8986):1339-1345.
9. Smith DW, Wiegeshaus EH, Edwards ML. The Protective Effects of BCG Vaccination Against Tuberculosis. In: Bendinelli M and Friedman H, eds. Mycobacterium tuberculosis. Plenum Publishing Corporation, New York, 1988:341-370.
10. ten Dam HG. Research on BCG vaccination. Adv Tuberc Res 1984; 21:79-106.
11. Tripathy SP. The case for BCG. Ann Natl Acad Med Sci 1983; 19(1):11-21.
12. Lagranderie MR, Balazuc AM, Deriaud E, et al. Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains. Infect Immun 1996; 64(1):1-9.
13. Chan J, Kaufmann SHE. In: Bloom, ed. Immune Mechanisms of Protection, Pathogenesis and Control. Washington, D.C.: B. R. American Society of Microbiology, 1994.
14. Palmer CE, Long MW. Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. Am Rev Respir Dis 1966; 94(4):553-568.
15. Weiszfeiler JG, Karasseva V. Mixed mycobacterial infections. Rev Infect Dis 1981; 3(5):1081-1083.
16. Rook GA, Bahr GM, Stanford JL. The effect of two distinct forms of cell-mediated response to mycobacteria on the protective efficacy of BCG. Tubercle 1981; 62(1):63-68.
17. Stanford JL, Shield MJ, Rook GA. How environmental mycobacteria may predetermine the protective efficacy of BCG. Tubercle 1981; 62(1):55-62.
18. Brandt L, Feino Cunha J, Weinreich Olsen A, et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun 2002; 70(2):672-678.
19. Fine PE, Vynnycky E. The effect of heterologous immunity upon the apparent efficacy of (e.g. BCG) vaccines. Vaccine 1998; 16(20):1923-1928.
20. Fine PE, Rodrigues LC. Modern vaccines. Mycobacterial diseases. Lancet 1990; 335(8696):1016-1020.
21. Kristensen I, Aaby P, Jensen H. Routine vaccinations and child survival: follow up study in Guinea Bissau, West Africa. Br Med J 2000; 321(7274):1435-1438.
22. Aronson NE, Santosham M, Comstock GW, et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study. JAMA 2004, 291(17):2127-2128.
23. Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393(6685): 537-544.
24. Izzo A, Brandt L, Lasco T, et al. NIH pre-clinical screening program: overview and current status. Tuberculosis (Edinb) 2005; 85(1-2):25-28.
25. Williams A, James BW, Bacon J, et al. An assay to compare the infectivity of Mycobacterium tuberculosis isolates based on aerosol infection of guinea pigs and assessment of bacteriology. Tuberculosis (Edinb) 2005; 85(3):177-184.
26. Demangel C, Brodin P, et al. Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RD1 immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6. Infect Immun 2004; 72(4):2170-2176.
27. Pym AS, Brodin P, et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 2003; 9(5):533-539.
28. Perez E, Samper S, Bordas Y, et al. An essential role for phoP in Mycobacterium tuberculosis virulence. Mol Microbiol 2001; 41(1):179-187.
29. Hess J, Miko D, Catic A, et al. Mycobacterium bovis Bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes. Proc Natl Acad Sci USA 1998; 95(9):5299-5304.
30. Grode L, Seiler P, Baumann S, et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Inv 2005; 115(9):2472-2479.
31. Louise R, Skjot V, Agger EM, et al. Antigen discovery and tuberculosis vaccine development in the post-genomic era. Scand J Infect Dis 2001; 33(9):643-647.
32. Sherman DR, Voskuil M, Schnappinger D, et al. Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha-crystallin. Proc Natl Acad Sci USA 2001; 98(13):7534-7539.
33. Dillon DC, Alderson MR, Day CH, et al. Molecular characterisation and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family. Infect Immun 1999; 67(6):2941-2950.
34. Horwitz MA, Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun 2003; 71(4):1672-1679.
35. Horwitz MA, Harth G, et al. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 2000; 97(25):13853-13858.
36. Fonseca DP, Benaissa-Trouw B, van Engelen M, et al. Induction of cell-mediated immunity against Mycobacterium tuberculosis using DNA vaccines encoding cytotoxic and helper T-cell epitopes of the 38-kilodalton protein. Infect Immun 2001; 69(8):4839-4845.
37. Lowrie DB, Tascon RE, Bonato VL, et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999; 400(6741):269-271.
38. Stanford JL, De las Aguas J, Turres P, et al. Studies on the effects of a potential immunotherapeutic agent in leprosy patients. Health Coop Pap 1987; 7:201-206.
39. Hondalus MK, Bardarov S, et al. Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis. Infect Immun 2000; 68(5): 2888-2898.
40. Smith DA, Parish T, et al. Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect Immun 2001; 69(2):1142-1150.
41. Campos JM, Simonetti JP, et al. Disseminated Bacillus Calmette-Guerin infection in HIV-infected children: case report and review. Pediatr AIDS HIV Infect 1996; 7(6):429-432.
42. Brosch R, Gordon SV, et al. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl Acad Sci USA 2002; 99(6):3684-3689.
43. Murray PJ, Aldovini A, Young RA. Manipulation and potentiation of antimycobacterial immunity using recombinant Bacille Calmette-Guerin strains that secrete cytokines. Proc Natl Acad Sci USA 1996; 93(2):934-939.
44. Sousa AO, Mazzaccaro RJ, Russell RG, et al. Relative contributions of distinct MHC class I-dependent cell populations in protection to tuberculosis infection in mice. Proc Natl Acad Sci USA 2000; 97(8):4204-4208.
45. Flynn JL, Goldstein MM, Triebold KJ, et al. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 1992; 89(24):12013-12017.
46. Edwards KM, Cynamon MH, Voladri RKR. Iron-cofactored superoxide dismutase inhibits host responses to Mycobacterium tuberculosis. Am J Respir Crit Care Med 2001; 164:2213-2219.
47. Reed MB, Domenech P, Manca C, et al. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature 2004; 431d(7004): 84-87.
48. Andersen P. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect Immun 1994; 62(6):2536-2544.
49. Andersen P, Askgaard D, Ljungqvist L, et al. Proteins released from Mycobacterium tuberculosis during growth. Infect Immun 1991; 59(6):1905-1910.
50. Content J, de la Cuvellerie A, de Wit L, et al. The genes coding for the antigen 85 complexes of Mycobacterium tuberculosis and Mycobacterium bovis BCG are members of a gene family: cloning, sequence determination, and genomic organization of the gene coding for antigen 85-C of M. tuberculosis. Infect Immun 1991; 59(9):3205-3212.
51. Berthet FX, Rasmussen PB, Rosenkrands I, et al. A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10). Microbiology 1998; 144(Pt 11):3195-3203.
52. Alderson MR, Bement T, Day CH, et al. Expression cloning of an immunodominant family of Mycobacterium tuberculosis antigens using human CD4(+) T cells. J Exp Med 2000; 191(3):551-560.
53. Skeiky YA, Alderson MR, Ovendale PJ, et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 2004; 172(12):7618-7628.
54. Reed SG, Alderson MR, Dalemans W, et al. Prospects for a better vaccine against tuberculosis [Review]. Tuberculosis (Edinb) 2003; 83(1-3):213-219.
55. Munk ME, Emoto M. Functions of T-cell subsets and cytokines in mycobacterial infections. Eur Respir J Suppl 1995; 20:668s-675s.
56. Chackerian AA, Perera TV, Behar SM. Gamma interferon-producing CD4+ T lymphocytes in the lung correlate with resistance to infection with Mycobacterium tuberculosis. Infect Immun 2001; 69(4):2666-2674.
57. van Pinxteren LA, Cassidy JP, Smedegaard BH, et al. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol 2000; 30(12):3689-3698.
58. Canaday DH, Wilkinson RJ, Li Q. CD4(+) and CD8(+) T cells kill intracellular Mycobacterium tuberculosis by a perforin and Fas/Fas ligand-independent mechanism. J Immunol 2001; 167(5):2734-2742.
59. Serbina NV, Flynn JL. CD8(+) T cells participate in the memory immune response to Mycobacterium tuberculosis. Infect Immun 2001; 69(7):4320-4328.
60. Stenger S. Cytolytic T cells in the immune response to mycobacterium tuberculosis. Scand J Infect Dis 2001; 33(7):483-487.
61. Turner J, D’Souza CD, Pearl JE, et al. CD8- and CD95/95L-dependent mechanisms of resistance in mice with chronic pulmonary tuberculosis. Am J Respir Cell Mol Biol 2001; 24(2):203-209.
62. Vordermeier HM, Zhu X, Harris DP. Induction of CD8+ CTL recognizing mycobacterial peptides. Scand J Immunol 1997; 45(5):521-526.
63. Zhu X, Venkataprasad N, Thangaraj HS, et al. Functions and specificity of T cells following nucleic acid vaccination of mice against Mycobacterium tuberculosis infection. J Immunol 1997; 158(12):5921-5926.
64. McShane H, Pathan AA, Sander CR. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004; 10(11):1240-1244.
65. McShane H, Pathan AA, Sander CR, et al. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinb) 2005; 85(1-2):47-52.
66. Kaufmann SH, McMichael AJ. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat Med 2005; 11(4):S33-S44.
67. Kaufmann SH. Gamma/delta and other unconventional T lymphocytes: what do they see and what do they do? Proc Natl Acad Sci USA 1996; 93(6):2272-2279.
68. Moody DB, Ulrichs T, Muhlecker W, et al. CD1c-mediated T-cell recognition of iso-prenoid glycolipids in Mycobacterium tuberculosis infection. Nature 2000; 404(6780):884-888.
69. Poziak A, Stanford JL, Johnson NMCL, et al. Preliminary studies of immunotherapy of tuberculosis in man. Proceedings of the International Tuberculosis Congress, Singapore. Bull IUALD 1987; 62:39-40.
70. Bahr GM, Shaaban MA, Gabriel M, et al. Improved immunotherapy for pulmonary tuberculosis with improved Mycobacterium vaccae. Tubercle 1990; 71:259-266.
71. Stanford JL, Bahr GM, Bypass O, et al. A modern approach to the immunotherapy of tuberculosis. Bull IUTLD 1990; 65:27-29.
72. Durban Immunotherapy Trial Group. Immunotherapy with Mycobacterium vaccae in patients with newly diganosed pulmonary tuberculosis: a randomised controlled trial. Lancet 1999; 354:116-119.
73. Orme IM. Mouse and guinea pig models for testing new tuberculosis vaccines. Tuberculosis 2005; 85:13-17.
74. Fine PE, Sterne JA, Ponnighaus JM, et al. Delayed-type hypersensitivity, mycobacterial vaccines and protective immunity. Lancet 1994; 344(8932):1245-1249.
75. Cooper AM, Dalton DK, Stewart TA, et al. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 1993; 178(6):2243-2247.
76. Agger EM, Andersen P. Tuberculosis subunit vaccine development: on the role of interferon-gamma. Vaccine 2001; 19(17-19):2298-2302.
77. Vordermeier HM, Chambers MA, Cockle PJ, et al. Correlation of ESAT-6-specific gamma interferon production with pathology in cattle following Mycobacterium bovis BCG vaccination against experimental bovine tuberculosis. Infect Immun 2002; 70(6):3026-3032.
78. McMurray DN. A coordinated strategy for evaluating new vaccines for human and animal tuberculosis. Tuberculosis (Edinb) 2001; 81(1-2):141-146.